Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 36, Issue 1, 2009, Pages 89-95

  Askanase, Anca D ^a,d   Wallace, Daniel J ^b   Weisman, Michael H ^b   Tseng, Chung E ^a   Bernstein, Lana ^a   Belmont, H Michael ^a   Seidman, Ernest ^c   Ishimori, Mariko ^b   Izmirly, Peter M ^a   Buyon, Jill P ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 thioguanine; Azathioprine; Metabolite; Monitoring; Systemic lupus erythematosus; Treatment

Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; PREDNISONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADULT; AGED; ALLERGIC RASH; ARTHRITIS; ARTICLE; BLOATING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERYTHROCYTE; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLITE; NAUSEA; NEPHRITIS; NEUTROPHIL COUNT; PARAMETER; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; RASH; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HETEROZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHYLTRANSFERASES; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACOGENETICS; PHENOTYPE; THIOGUANINE; YOUNG ADULT;

EID: 58149517583     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.070968     Document Type: Article

References (26)

1. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
2. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72.
3. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
4. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
5. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000;14:1009-14.
6. Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005;35:580-5.
7. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130:1047-53.
8. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15.
9. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
10. Seidman E. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003;3 Suppl:S30-8.
11. Petri M, Barr SG, Buyon J, Davis J, Ginzler E, Kalunian K. RIFLE: Responder Index for Lupus Erythematosus [abstract]. Arthritis Rheum 2000;43 Suppl:S244.
12. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
13. Petri M, Kim MY, Kalunian KC, et al; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
14. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Lennard L, Singleton H. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B: Biomed Appl 1994;661:25-33.
17. Kröplin T, Weyer N, Iven H. Purine and pyrimidine metabolism in man. IX. New York: Plenum Press; 1998:741-5.
18. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
19. Tai H-L, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency. Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
20. Zaza G, Cheok M, Yang W, Panetta JC, Relling C, Evans W. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005;106:1778-85.
21. Dervieux T, Brenner TL, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002;100:1240-7.
22. Cuffari C, Théorêt Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
23. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-91.
24. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
25. Bergan S. Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements. BioDrugs 1997;8:446-56.
26. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87.